A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.

Administered By

Duke Cancer Institute

Awarded By

Innocrin Pharmaceutical, Inc.

Contributors

Marcom, Paul Kelly Principal Investigator

Start/End

August 26, 2016 - August 27, 2019